AHCO vs INSP
AHCO: AdaptHealth delivers home medical equipment, supplies, and chronic disease management services directly to patients, focusing on sleep apnea, respiratory diseases, diabetes, and post-acute recovery. INSP: Inspire Medical Systems manufactures implantable nerve stimulation devices that treat obstructive sleep apnea without surgery or continuous positive airway pressure (CPAP).
Side-by-side fundamentals
| Metric | AHCO | INSP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.88 | $50.40 | |
| Market cap as of 2026-07-23 | $1.5B | $1.5B | |
| P/E as of 2026-07-23 | n/a | 11.06 | |
| PEG as of 2026-07-23 | n/a | 0.11 | |
| Net margin as of 2026-07-23 | -2.4% | +14.3% | INSP higher |
| Gross margin as of 2026-07-23 | +20.6% | +85.8% | INSP higher |
| Operating margin as of 2026-07-23 | +2.2% | +5.2% | INSP higher |
| ROE as of 2026-07-23 | -5.1% | +18.0% | INSP higher |
| ROA as of 2026-07-23 | -1.8% | +15.3% | INSP higher |
| Debt / equity as of 2026-07-23 | 1.24 | 0.00 | INSP lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | +8.9% | INSP higher |
| Revenue CAGR (3y) SEC XBRL | +3.0% | +30.8% | INSP higher |
| Beta as of 2026-07-23 | 1.47 | 0.66 | |
| 1-year return as of 2026-07-22 close | +22.5% | -61.1% | AHCO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.